Semaglutide is still under patent protection, meaning only the brand-name version is available
Semaglutide works mainly through GLP-1 receptors, while tirzepatide works through both GLP-1 and GIP receptor pathways
A: No, a valid prescription is required
Continuous support guarantees that your treatment stays effective while allowing you to make informed choices about your well-being
Tai JE, Phillips CL, Yee BJ, Grunstein RR
doi: 10.3389/fcvm.2025.1731127 Received 23 October 2025 Revised 15 November 2025 Accepted 28 November 2025 Published 15 December 2025 Volume 12 - 2025 Edited by Manfredi Tesauro, University of Rome Tor Vergata, Italy Reviewed by Angelo Maria Patti, University of Palermo, Italy Antonio Maria Labate, ASST Franciacorta, Italy Updates Copyright 2025 Tan, Yin and Lu